Akorn, Inc. has entered into a 10-year exclusive contract manufacturing supply agreement with an undisclosed pharmaceutical firm. Under the terms of the agreement, Akorn will be responsible for the manufacturing and supply of several injectable drug products. Akorn anticipates annual contract revenue from these products to be between $4 million and $5 million for the duration of the supply agreement.     Arthur S. Przybyl, Akorn’s president and chief executive officer stated, “This agreement ...